Mark your calendars: Eli Lilly will come before the FDA’s advisory committee to discuss Alzheimer’s disease medicine donanemab June 10. The Peripheral and Central Nervous System Drugs Advisory ...

An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain edema and effusion but still maintained sufficient amyloid reduction in early Alzheimer's disease, the ...

A “powerful and meaningful” drug is offering new hope in the battle against Alzheimer’s disease — with scientists hailing it as a “huge opportunity” for patients suffering from early onset dementia.

The experimental Alzheimer's drug donanemab can modestly slow the worsening of the mind-robbing disease by about four to seven months, researchers reported Monday. In May, Lilly announced donanemab ...

Before this announcement, a regulatory decision was expected in the first quarter of 2024. The Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS ...

The U.S. Food and Drug Administration has delayed action for the promising Alzheimer’s treatment donanemab, the drug manufacturer said on Friday. Eli Lilly said the FDA would wait on ruling about ...

AMSTERDAM (AP) — Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food ...

(CNN) — The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease. Donanemab, made by ...

Please provide your email address to receive an email when new articles are posted on . Eli Lilly & Co.’s donanemab slowed cognitive and functional decline in people with early Alzheimer’s. The phase ...